{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T20:58:21Z","timestamp":1764277101189},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The mechanism of volatile anesthetics on vascular smooth muscle (VSM) contraction in the setting of diabetes mellitus (DM) remains unclear. The current study was designed to determine the effects of sevoflurane (SEVO) and isoflurane (ISO) on phosphoinositide 3-kinase (PI3K) and Rho kinase (ROCK) mediated KCl-induced vasoconstriction in aged type 2 diabetic rats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>KCl-induced (60\u00a0mM) contractions were examined in endothelium-denuded aortic rings from aged T2DM Otsuka Long-Evans Tokushima Fatty (OLETF) rats (65\u201370\u00a0weeks old), control age-matched nondiabetic Long-Evans Tokushima Otsuka (LETO) rats and young Wistar rats (6\u20138\u00a0weeks old). The effects of SEVO or ISO (1\u20133 minimum alveolar concentration, MAC) on KCl-induced vasoconstriction, as well as those of LY294002 (PI3K inhibitor) and Y27632 (ROCK inhibitor) were measured in aortic rings from the three groups using an isometric force transducer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>KCl induced rapid and continuous contraction of aortic smooth muscle in the three groups, and the contraction was more obvious in OLETF rats.<\/jats:p>\n                <jats:p>SEVO and ISO inhibited KCl-induced vasoconstriction in a concentration-dependent manner and were suppressed by LY294002 (10\u00a0\u00b5M) and Y27632 (1\u00a0\u00b5M). SEVO had a stronger inhibitory effect on the aortas of young Wistar rats than ISO, especially at 2 MAC and 3 MAC (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). In aged rats, the inhibitory effect of ISO was stronger than that of SEVO, especially OLETF rats. There was no significant difference in the effects of different concentrations of ISO on arterial contraction among the three groups (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). The effects of 1 MAC SEVO on Wistar rats and 3 MAC SEVO on OLETF rats, however, were noticeably and significantly different (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p>\n                <jats:p>Compared with the control condition, LY294002 and Y27632 had the most noticeable effect on the KCl-induced contraction of aortic rings in OLETF rats (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SEVO (3 MAC), ISO (1, 2, 3 MAC), LY294002 and Y27632 have more significant inhibitory effect on the contraction of vascular smooth muscle in aged T2MD rats. The mechanism of SEVO and ISO in vascular tension in T2DM is partly due to changes in PI3K and\/or Rho kinase activity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12871-021-01425-3","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T08:04:22Z","timestamp":1630483462000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sevoflurane and isoflurane inhibit KCl-induced, Rho kinase-mediated, and PI3K-participated vasoconstriction in aged diabetic rat aortas"],"prefix":"10.1186","volume":"21","author":[{"given":"Shaozhong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feihong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"issue":"1","key":"1425_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","volume":"17","author":"C Rask-Madsen","year":"2013","unstructured":"Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17(1):20\u201333.","journal-title":"Cell Metab"},{"issue":"3","key":"1425_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"142","author":"K Huynh","year":"2014","unstructured":"Huynh K, Bernardo BC, McMullen JR, et al. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142(3):375\u2013415.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"1425_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3109\/14767058.2011.587921","volume":"25","author":"A Jiwani","year":"2012","unstructured":"Jiwani A, Marseille E, Lohse N, et al. Gestational diabetes mellitus: results from a survey of country prevalence and practices. J Matern Fetal Neonatal Med. 2012;25(6):600\u201310.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"9785","key":"1425_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","volume":"378","author":"G Danaei","year":"2011","unstructured":"Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2\u00b77 million participants. Lancet. 2011;378(9785):31\u201340.","journal-title":"Lancet"},{"issue":"4","key":"1425_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1536\/ihj.17-191","volume":"58","author":"R Naito","year":"2017","unstructured":"Naito R, Miyauchi K. Coronary artery disease and type 2 diabetes mellitus current treatment strategies and future perspective. Int Heart J. 2017;58(4):17\u2013191.","journal-title":"Int Heart J"},{"issue":"17","key":"1425_CR6","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/CIRCULATIONAHA.107.185700","volume":"116","author":"LA Fleisher","year":"2007","unstructured":"Fleisher LA, Beckman JA, Brown KA, et al. ACC\/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation. 2007;116(17):1971\u201396.","journal-title":"Circulation"},{"issue":"2","key":"1425_CR7","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1161\/01.RES.88.2.e14","volume":"88","author":"U Hink","year":"2001","unstructured":"Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88(2):e14\u201322.","journal-title":"Circ Res"},{"issue":"2","key":"1425_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1006\/bbrc.1993.2111","volume":"195","author":"F Kanai","year":"1993","unstructured":"Kanai F, Ito K, Todaka M, et al. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3 kinase. Biochem Biophys Res Commun. 1993;195(2):762\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1425_CR9","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1016\/S0021-9258(17)41901-6","volume":"269","author":"T Okada","year":"1994","unstructured":"Okada T, Kawano Y, Sakakibara T, et al. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem. 1994;269(5):3568\u201373.","journal-title":"J Biol Chem"},{"issue":"1","key":"1425_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8400","volume":"6","author":"L Braccini","year":"2015","unstructured":"Braccini L, Ciraolo E, Campa CC, et al. PI3K-C2\u03b3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat Commun. 2015;6(1):1\u201315.","journal-title":"Nat Commun"},{"issue":"6736","key":"1425_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/21224","volume":"399","author":"S Dimmeler","year":"1999","unstructured":"Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399(6736):601\u20135.","journal-title":"Nature"},{"issue":"5573","key":"1425_CR12","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655\u20137.","journal-title":"Science"},{"issue":"12","key":"1425_CR13","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.3390\/ijms19124098","volume":"19","author":"A Maffei","year":"2018","unstructured":"Maffei A, Lembo G, Carnevale D. PI3Kinases in diabetes mellitus and its related complications. Int J Mol Sci. 2018;19(12):4098.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1425_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-018-0809-2","volume":"17","author":"S Bathina","year":"2018","unstructured":"Bathina S, Das UN. Dysregulation of PI3K-Akt-mTOR pathway in brain of streptozotocin-induced type 2 diabetes mellitus in Wistar rats. Lipids Health Dis. 2018;17(1):1\u201311.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"1425_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.yexmp.2016.10.002","volume":"101","author":"RC Torres","year":"2016","unstructured":"Torres RC, Magalh\u00e3es NS, e Silva PMR, et al. Activation of PPAR-\u03b3 reduces HPA axis activity in diabetic rats by up-regulating PI3K expression. Exp Mol Pathol. 2016;101(2):290\u2013301.","journal-title":"Exp Mol Pathol"},{"issue":"4","key":"1425_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1161\/HYPERTENSIONAHA.113.02296","volume":"63","author":"M Kajikawa","year":"2014","unstructured":"Kajikawa M, Noma K, Maruhashi T, et al. Rho-associated kinase activity is a predictor of cardiovascular outcomes. Hypertension. 2014;63(4):856\u201364.","journal-title":"Hypertension"},{"key":"1425_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01027-2","volume":"19","author":"MP Ocaranza","year":"2020","unstructured":"Ocaranza MP, Valderas P, Moya J, et al. Rho kinase cascade activation in circulating leukocytes in patients with diabetes mellitus type 2. Cardiovasc Diabetol. 2020;19:1\u201312.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1425_CR18","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1161\/ATVBAHA.111.227892","volume":"31","author":"J Soga","year":"2011","unstructured":"Soga J, Noma K, Hata T, et al. Rho-associated kinase activity, endothelial function, and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011;31(10):2353\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1425_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00000542-200702000-00026","volume":"106","author":"T Akata","year":"2007","unstructured":"Akata T, Warltier DC. General anesthetics and vascular smooth muscle: direct actions of general anesthetics on cellular mechanisms regulating vascular tone. Anesthesiology. 2007;106(2):365\u201391.","journal-title":"Anesthesiology"},{"issue":"3","key":"1425_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1097\/00000542-200309000-00020","volume":"99","author":"J Yu","year":"2003","unstructured":"Yu J, Ogawa K, Tokinaga Y, et al. Sevoflurane inhibits guanosine 5\u2032-[\u03b3-thio] triphosphate\u2013stimulated, Rho\/Rho-kinase\u2013mediated contraction of isolated rat aortic smooth muscle. Anesthesiology. 2003;99(3):646\u201351.","journal-title":"Anesthesiology"},{"issue":"4","key":"1425_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/00000542-200404000-00018","volume":"100","author":"J Yu","year":"2004","unstructured":"Yu J, Tokinaga Y, Ogawa K, et al. Sevoflurane inhibits angiotensin II\u2013induced, protein kinase C\u2013mediated but not Ca2+-elicited contraction of rat aortic smooth muscle. Anesthesiology. 2004;100(4):879\u201384.","journal-title":"Anesthesiology"},{"issue":"2","key":"1425_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1213\/ane.0b013e3181ac6d96","volume":"109","author":"F Qi","year":"2009","unstructured":"Qi F, Ogawa K, Tokinaga Y, et al. Volatile anesthetics inhibit angiotensin II-induced vascular contraction by modulating myosin light chain phosphatase inhibiting protein, CPI-17 and regulatory subunit, MYPT1 phosphorylation. Anesth Analg. 2009;109(2):412\u20137.","journal-title":"Anesth Analg"},{"issue":"1","key":"1425_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12871-016-0227-9","volume":"16","author":"S Yang","year":"2015","unstructured":"Yang S, Wu Q, Huang S, et al. Sevoflurane and isoflurane inhibit KCl-induced Class II phosphoinositide 3-kinase \u03b1 subunit mediated vasoconstriction in rat aorta. BMC Anesthesiol. 2015;16(1):63.","journal-title":"BMC Anesthesiol"},{"key":"1425_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lfs.2017.04.005","volume":"177","author":"Y Miyamoto","year":"2017","unstructured":"Miyamoto Y, Feng GG, Satomi S, et al. Phosphatidylinositol 3-kinase inhibition induces vasodilator effect of sevoflurane via reduction of Rho kinase activity. Life Sci. 2017;177:20\u20136.","journal-title":"Life Sci"},{"issue":"12","key":"1425_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s12630-010-9387-0","volume":"57","author":"K Fujii","year":"2010","unstructured":"Fujii K, Ogawa K, Tokinaga Y, et al. Sevoflurane does not alter norepinephrine-induced intracellular Ca2+ changes in the diabetic rat aorta. Can J Anaesth. 2010;57(12):1095\u2013101.","journal-title":"Can J Anaesth"},{"issue":"1","key":"1425_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.anes.0000268388.30053.1e","volume":"107","author":"T Negoro","year":"2007","unstructured":"Negoro T, Mizumoto K, Ogawa K, et al. Effects of isoflurane and sevoflurane anesthesia on arteriovenous shunt flow in the lower limb of diabetic patients without autonomic neuropathy. Anesthesiology. 2007;107(1):45\u201352.","journal-title":"Anesthesiology"},{"key":"1425_CR27","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1016\/0168-8227(94)90269-0","volume":"24","author":"K Kawano","year":"1994","unstructured":"Kawano K, Hirashima T, Mori S, et al. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract. 1994;24:S317\u201320.","journal-title":"Diabetes Res Clin Pract"},{"key":"1425_CR28","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals","year":"2011","unstructured":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press (US); 2011.","edition":"8"},{"key":"1425_CR29","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"1425_CR30","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s00210-017-1396-x","volume":"390","author":"MZ Islam","year":"2017","unstructured":"Islam MZ, Van Dao C, Miyamoto A, et al. Rho-kinase and the nitric oxide pathway modulate basilar arterial reactivity to acetylcholine and angiotensin II in streptozotocin-induced diabetic mice. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(9):929\u201338.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"8","key":"1425_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00210-017-1379-y","volume":"390","author":"A Hofni","year":"2017","unstructured":"Hofni A, Messiha BAS, Mangoura SA. Fasudil ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats: a possible role of Rho kinase. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(8):801\u201311.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"1425_CR32","doi-asserted-by":"publisher","first-page":"H1166","DOI":"10.1152\/ajpheart.00464.2019","volume":"317","author":"TD Olver","year":"2019","unstructured":"Olver TD, Grunewald ZI, Ghiarone T, et al. Persistent insulin signaling coupled with restricted PI3K activation causes insulin-induced vasoconstriction. Am J Physiol Heart Circ Physiol. 2019;317(5):H1166\u201372.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1425_CR33","doi-asserted-by":"publisher","first-page":"109825","DOI":"10.1016\/j.biopha.2020.109825","volume":"125","author":"Y Liu","year":"2020","unstructured":"Liu Y, Wei J, Ma KT, et al. Carvacrol protects against diabetes-induced hypercontractility in the aorta through activation of the PI3K\/Akt pathway. Biomed Pharmacother. 2020;125:109825.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1425_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0003319707305692","volume":"59","author":"AG Ruitenbeek","year":"2008","unstructured":"Ruitenbeek AG, Van Der Cammen TJM, Van Den Meiracker AH, et al. Age and blood pressure levels modify the functional properties of central but not peripheral arteries. Angiology. 2008;59(3):290\u20135.","journal-title":"Angiology"},{"issue":"1","key":"1425_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/apha.12646","volume":"219","author":"PM Vanhoutte","year":"2017","unstructured":"Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017;219(1):22\u201396. https:\/\/doi.org\/10.1111\/apha.12646. Epub 2016 Jan. 25 PMID: 26706498.","journal-title":"Acta Physiol (Oxf)"},{"issue":"3","key":"1425_CR36","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1124\/jpet.104.082784","volume":"313","author":"K Budzyn","year":"2005","unstructured":"Budzyn K, Marley PD, Sobey CG. Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension. J Pharmacol Exp Ther. 2005;313(3):1248\u201353.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"1425_CR37","first-page":"89","volume":"24","author":"EI Eger II","year":"2005","unstructured":"Eger EI II. The pharmacology of inhaled anesthetics[C]\/\/Seminars in anesthesia, perioperative medicine and pain. WB Saunders. 2005;24(2):89\u2013100.","journal-title":"WB Saunders"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-021-01425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-021-01425-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-021-01425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:05:54Z","timestamp":1630526754000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-021-01425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1186\/s12871-021-01425-3","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"5 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by Shandong University Animal Care and Use Committee and Qilu Hospital of Shandong University Medical Ethics Committee (No.KYLL-2013\u201351), and all studies were conducted in accordance with \u2018\u2018Guide for the Care and Use of Laboratory Animals\u2019\u2019 published by the US National Institute of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}